Literature DB >> 2826090

Chemotactic activity in inflammatory bowel disease. Role of leukotriene B4.

E A Lobos1, P Sharon, W F Stenson.   

Abstract

An important histologic feature of inflammatory bowel disease (IBD) is infiltration of the colonic mucosa with neutrophils. To investigate the nature of the chemotactic agents responsible for this infiltration, colonic mucosa from three normals and nine patients with inflammatory bowel disease (seven ulcerative colitis, two Crohn's colitis) was assayed for chemotactic activity for human neutrophils in vitro in a Boyden chamber. There was more (greater than 10-fold more) chemotactic activity in homogenates of inflammatory bowel disease mucosa than in homogenates of normal colonic mucosa. Analysis of the chemotactic activity in the inflammatory bowel disease mucosa revealed that most was lipid extractable. Moreover, when the lipid extract was fractionated by reverse-phase high-pressure liquid chromatography, the only fraction with significant chemotactic activity was the fraction that coeluted with leukotriene B4. The chemotactic response to IBD mucosa was blocked by anti-LTB4 antisera. The amount of chemotactic activity in lipid extracts of different inflammatory bowel disease specimens correlated well with the concentration of leukotriene B4 measured by UV absorbance (250 ng/g of mucosa). These data suggest that leukotriene B4 is an important stimulus to neutrophil chemotaxis in inflammatory bowel disease and, thus, may play a major role in the amplification of the inflammatory response in this condition.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2826090     DOI: 10.1007/BF01296664

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

2.  Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine.

Authors:  P Sharon; M Ligumsky; D Rachmilewitz; U Zor
Journal:  Gastroenterology       Date:  1978-10       Impact factor: 22.682

3.  Leukotriene B4, an inflammatory mediator in gout.

Authors:  S A Rae; E M Davidson; M J Smith
Journal:  Lancet       Date:  1982-11-20       Impact factor: 79.321

4.  Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes.

Authors:  A W Ford-Hutchinson; M A Bray; M V Doig; M E Shipley; M J Smith
Journal:  Nature       Date:  1980-07-17       Impact factor: 49.962

5.  Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls.

Authors:  K Lauritsen; J Hansen; P Bytzer; K Bukhave; J Rask-Madsen
Journal:  Gut       Date:  1984-11       Impact factor: 23.059

6.  Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models.

Authors:  J E Krawisz; P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1984-12       Impact factor: 22.682

7.  Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes. Formation of a novel dihydroxyeicosatetraenoic acid.

Authors:  P Borgeat; B Samuelsson
Journal:  J Biol Chem       Date:  1979-04-25       Impact factor: 5.157

8.  Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease.

Authors:  P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1984-03       Impact factor: 22.682

9.  Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response.

Authors:  S E Dahlén; J Björk; P Hedqvist; K E Arfors; S Hammarström; J A Lindgren; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

10.  Metabolism of arachidonic acid in acetic acid colitis in rats. Similarity to human inflammatory bowel disease.

Authors:  P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1985-01       Impact factor: 22.682

View more
  35 in total

1.  Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial.

Authors:  A B Hawthorne; T K Daneshmend; C J Hawkey; A Belluzzi; S J Everitt; G K Holmes; C Malkinson; M Z Shaheen; J E Willars
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

Review 2.  Inflammatory intermediaries in inflammatory bowel disease.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

3.  Neutrophil differentiated HL-60 cells model Mac-1 (CD11b/CD18)-independent neutrophil transepithelial migration.

Authors:  Svetlana O Carrigan; Amy L Weppler; Andrew C Issekutz; Andrew W Stadnyk
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

Review 4.  Clinical relevance of oxygen radicals in inflammatory bowel disease--facts and fashion.

Authors:  H Allgayer
Journal:  Klin Wochenschr       Date:  1991-12-15

Review 5.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 6.  [Inhibition of intestinal leukotriene formation as a possible mechanism of action of sulfasalazine, 5-aminosalicylic acid and 4-aminosalicylic acid].

Authors:  B M Peskar
Journal:  Klin Wochenschr       Date:  1988-11-15

Review 7.  [What is the role of nutrition in ulcerative colitis? A contribution to the current status of diet therapy in treatment of inflammatory bowel diseases].

Authors:  M Bartels; E Nagel; R Pichlmayr
Journal:  Langenbecks Arch Chir       Date:  1995

8.  5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease.

Authors:  Y R Mahida; C E Lamming; A Gallagher; A B Hawthorne; C J Hawkey
Journal:  Gut       Date:  1991-01       Impact factor: 23.059

9.  Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase.

Authors:  B J R Whittle; C Varga; A Berko; K Horvath; A Posa; J P Riley; K A Lundeen; A M Fourie; P J Dunford
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

10.  Effect of leukotriene C4D4 antagonist on colonic damage induced by intracolonic administration of trinitrobenzene sulfonic acid in rats.

Authors:  M Nishikawa; Y Hikasa; K Hori; N Tanida; T Shimoyama
Journal:  J Gastroenterol       Date:  1995-02       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.